Narrative review of stereotactic body radiation therapy combined with tyrosine kinase inhibitors for oligometastatic EGFR-mutated non-small cell lung cancer: present and future developments
机构：[1]School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.[2]Cancer Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.四川省人民医院[3]UPMC Hillman Cancer Center, San Pietro, Rome, Italy.[4]Department of Radiation Oncology, UMass Chan Medical School, Worcester, MA, USA.[5]Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.[6]Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA.[7]Department of Breast Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.四川省人民医院
A significant number of individuals diagnosed with non-small cell lung cancer (NSCLC) have distant metastases, and the concept of oligometastatic NSCLC has shown promise in achieving a cure. Stereotactic body radiation therapy (SBRT) is currently considered a viable treatment option for a limited number of tumor metastases. It has also been demonstrated that third-generation tyrosine kinase inhibitors (TKIs) are effective in extending the survival of patients with epidermal growth factor receptor (EGFR)-mutated NSCLC. Hence, the combination of SBRT with third-generation TKIs holds the potential to enhance treatment efficacy in patients with oligometastatic EGFR-mutated NSCLC. This review aimed to assess the possibility of combining SBRT with TKIs as an optimum treatment option for patients with oligometastatic EGFR-mutated NSCLC.We performed a narrative review by searching the PubMed, Web of Science, Elsevier and ClinicalTrials.gov databases for articles published in the English language from January 2009 to February 2024 and by reviewing the bibliographies of key references to identify important literature related to combining SBRT with third-generation TKIs in oligometastatic EGFR-mutated NSCLC.This review aimed to assess the viability of combining SBRT and EGFR-TKIs in oligometastatic EGFR-mutated NSCLC. Current clinical trials suggest that the combined therapies have better progression free survival (PFS) when using SBRT as either concurrent with EGFR-TKIs or consolidated with EGFR-TKIs. Furthermore, research with third-generation EGFR-TKIs and SBRT combinations has demonstrated tolerable toxicity levels without significant additional adverse effects as compared to prior therapies. However, further clinical trials are required to establish its effectiveness.The combined approach of SBRT and TKIs can effectively impede the progression of oligometastatic NSCLC in patients harboring EGFR mutations and, most notably, can prolong progression-free survival rates. However, the feasibility of combining SBRT with third-generation TKIs in clinical trials remains unclear.2024 Translational Lung Cancer Research. All rights reserved.
基金：
This work was supported by the Sichuan Science and Technology Program (No. 2022YFS0212), the Chengdu Science and Technology Innovation Research and Development Project (No. 2021-YF05-02143-SN), and the Clinical Research and Transformation Fund of Sichuan Provincial People’s Hospital (No. 2021LY25).
第一作者机构：[1]School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Zhao Xinchen,Zhang Shengwei,Sun Xiaoyue,et al.Narrative review of stereotactic body radiation therapy combined with tyrosine kinase inhibitors for oligometastatic EGFR-mutated non-small cell lung cancer: present and future developments[J].Translational Lung Cancer Research.2024,13(6):1383-1395.doi:10.21037/tlcr-24-414.
APA：
Zhao Xinchen,Zhang Shengwei,Sun Xiaoyue,Lin Yao,Capone Luca...&Wang Xiaoshan.(2024).Narrative review of stereotactic body radiation therapy combined with tyrosine kinase inhibitors for oligometastatic EGFR-mutated non-small cell lung cancer: present and future developments.Translational Lung Cancer Research,13,(6)
MLA：
Zhao Xinchen,et al."Narrative review of stereotactic body radiation therapy combined with tyrosine kinase inhibitors for oligometastatic EGFR-mutated non-small cell lung cancer: present and future developments".Translational Lung Cancer Research 13..6(2024):1383-1395
